Modulation of type I IL-1 receptor and IL-1 beta mRNA expression followed by endotoxin treatment in the corticotropin-releasing hormone-deficient mouse.
In an attempt to define the possible role of corticotropin-releasing hormone (CRH) on lipopolysaccharide (LPS)-induced type I interleukin-1 receptor (IL-1R1), IL-1alpha, and IL-1beta mRNAs in the pituitary, adrenal gland and spleen, we used CRH-deficient (knockout, KO) mouse in this study. LPS administration resulted in a robust increase in IL-1R1 mRNA levels in the pituitary, adrenal gland and spleen of wild-type (WT) and CRH KO mice, but this elevation was attenuated in the pituitary and adrenal gland of CRH KO mice. CRH deficiency did not affect LPS administration induced increase of IL-1alpha mRNA as well as IL-1beta mRNA in the pituitary and adrenal gland. Lack of CRH attenuated LPS administration induced increase of IL-1beta mRNA expression in the spleen. These data demonstrate the pivotal and organ-specific modulation of CRH for IL-1 and IL-1R1 mRNAs following endotoxin treatment.
Pournajafi Nazarloo
Hossein
H
Second Department of Internal Medicine, Kochi Medical School, Kohasu, Okoh-cho, Nankoku 783-8505, Japan. pour@med.kochi-ms.ac.jp
Takao
Toshihiro
T
Taguchi
Takafumi
T
Ito
Hiroyuki
H
Hashimoto
Kozo
K
D000311:Adrenal Glands / Q000276:immunology / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000818:Animals; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000172:deficiency* / Q000235:genetics* / Q000502:physiology; D005260:Female; D007274:Injections, Intraperitoneal; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics; D008070:Lipopolysaccharides / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009928:Organ Specificity / Q000235:genetics / Q000276:immunology; D010902:Pituitary Gland / Q000276:immunology / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics; D053573:Receptors, Interleukin-1 Type I; D012965:Sodium Chloride / Q000008:administration & dosage; D013154:Spleen / Q000276:immunology / Q000378:metabolism; D015854:Up-Regulation / Q000235:genetics / Q000276:immunology
D007375:Interleukin-1; D008070:Lipopolysaccharides; D012333:RNA, Messenger; D017472:Receptors, Interleukin-1; D053573:Receptors, Interleukin-1 Type I; D012965:Sodium Chloride; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D003345:Corticosterone